Search Results - "Francis, Donald P"

Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV-1 Infection in a Phase 3 HIV-1 Preventive Vaccine Trial by Gilbert, Peter B., Peterson, Michael L., Follmann, Dean, Hudgens, Michael G., Francis, Donald P., Gurwith, Marc, Heyward, William L., Jobes, David V., Popovic, Vladimir, Self, Steven G., Sinangil, Faruk, Burke, Donald, Berman, Phillip W.

“…BackgroundAn objective of the first efficacy trial of a candidate vaccine containing recombinant human immunodeficiency virus (HIV) type 1 envelope…”
Get full text

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women by Gilbert, Peter B, Excler, Jean-Louis, Tomaras, Georgia D, Carpp, Lindsay N, Haynes, Barton F, Liao, Hua-Xin, Montefiori, David C, Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Kijak, Gustavo H, Tovanabutra, Sodsai, Francis, Donald P, Lee, Carter, Sinangil, Faruk, Berman, Phillip W, Premsri, Nakorn, Kunasol, Prayura, O'Connell, Robert J, Michael, Nelson L, Robb, Merlin L, Morrow, Rhoda, Corey, Lawrence, Kim, Jerome H

“…In the HIV-1 vaccine trial RV144, ALVAC-HIV prime with an AIDSVAX® B/E boost reduced HIV-1 acquisition by 31% at 42 months post first vaccination. The bivalent…”
Get full text

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand by Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Bussaratid, Valai, Dhitavat, Jittima, Maekanantawat, Wirach, Pungpak, Swangjai, Suntharasamai, Pravan, Vanijanonta, Sirivan, Nitayapan, Sorachai, Kaewkungwal, Jaranit, Benenson, Michael, Morgan, Patricia, O'Connell, Robert J, Berenberg, Jeffrey, Gurunathan, Sanjay, Francis, Donald P, Paris, Robert, Chiu, Joseph, Stablein, Donald, Michael, Nelson L, Excler, Jean-Louis, Robb, Merlin L, Kim, Jerome H

“…A prime-boost vaccination regimen with ALVAC-HIV (vCP1521) administered intramuscularly at 0, 4, 12, and 24 weeks and gp120 AIDSVAX B/E at 12 and 24 weeks…”
Get full text

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens by Karasavvas, Nicos, Karnasuta, Chitraporn, Savadsuk, Hathairat, Madnote, Sirinan, Inthawong, Dutsadee, Chantakulkij, Somsak, Rittiroongrad, Surawach, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Thongcharoen, Prasert, Siriyanon, Vinai, Andrews, Charla A, Barnett, Susan W, Tartaglia, James, Sinangil, Faruk, Francis, Donald P, Robb, Merlin L, Michael, Nelson L, Ngauy, Viseth, de Souza, Mark S, Paris, Robert M, Excler, Jean-Louis, Kim, Jerome H, O'Connell, Robert J

“…RV144 correlates of risk analysis showed that IgG antibodies to gp70V1V2 scaffolds inversely correlated with risk of HIV acquisition. We investigated IgG…”
Get more information

Dengue vaccines regulatory pathways: a report on two meetings with regulators of developing countries by Mahoney, Richard, Chocarro, Liliana, Southern, James, Francis, Donald P, Vose, John, Margolis, Harold

“…Abbreviations: DCVRN, Developing Countries' Vaccine Regulators Network; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; EMA, European Agency for the…”
Get full text

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand by Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Chiu, Joseph, Paris, Robert, Premsri, Nakorn, Namwat, Chawetsan, de Souza, Mark, Adams, Elizabeth, Benenson, Michael, Gurunathan, Sanjay, Tartaglia, Jim, McNeil, John G, Francis, Donald P, Stablein, Donald, Birx, Deborah L, Chunsuttiwat, Supamit, Khamboonruang, Chirasak, Thongcharoen, Prasert, Robb, Merlin L, Michael, Nelson L, Kunasol, Prayura, Kim, Jerome H

“…With more than 7000 new HIV infections each day, there is a tremendous need for a prophylactic HIV vaccine. In this study involving more than 16,000 largely…”
Get full text

HIV-1 Virologic and Immunologic Progression and Initiation of Antiretroviral Therapy among HIV-1–Infected Subjects in a Trial of the Efficacy of Recombinant Glycoprotein 120 Vaccine by Gilbert, Peter B., Ackers, Marta L., Berman, Phillip W., Francis, Donald P., Popovic, Vladimir, Hu, Dale J., Heyward, William L., Sinangil, Faruk, Shepherd, Bryan E., Gurwith, Marc

“…The first trial of the efficacy of a human immunodeficiency virus (HIV)–1 vaccine was conducted in North America and The Netherlands between 1998 and 2003…”
Get full text

Challenges and successes for the grantees and the Technical Advisory Group of WHO’s influenza vaccine technology transfer initiative by Grohmann, Gary, Francis, Donald P, Sokhey, Jaspal, Robertson, James

“…Abstract One of the aims of the WHO Global Action Plan for Influenza Vaccines (GAP) was to transfer influenza vaccine production technology to interested…”
Get full text

Phase I/II Study of a Candidate Vaccine Designed Against the B and E Subtypes of HIV-1 by Pitisuttithum, Punnee, Berman, Phillip W, Phonrat, Benjaluck, Suntharasamai, Pravan, Raktham, Suwanee, Srisuwanvilai, La-Ong, Hirunras, Krit, Kitayaporn, Dwip, Kaewkangwal, Jaranit, Migasena, Sricharoen, Sheppard, Haynes W, Li, Elizabeth, Chernow, Marlene, Peterson, Michael L, Shibata, Riri, Heyward, William L, Francis, Donald P

“…SUMMARYA phase I/II trial of a candidate vaccine to prevent HIV infection was carried out in Bangkok, Thailand, testing AIDSVAX B/E (VaxGen, Inc., Brisbane,…”
Get full text

Deadly AIDS policy failure by the highest levels of the US government: A personal look back 30 years later for lessons to respond better to future epidemics by Francis, Donald P

“…Successful control of any dangerous epidemic requires: (i) early understanding of the epidemiology of the disease and (ii) rapid applications of preventive…”
Get full text

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens by Karnasuta, Chitraporn, Akapirat, Siriwat, Madnote, Sirinan, Savadsuk, Hathairat, Puangkaew, Jiraporn, Rittiroongrad, Surawach, Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Tartaglia, James, Sinangil, Faruk, Francis, Donald P, Robb, Merlin L, de Souza, Mark S, Michael, Nelson L, Excler, Jean-Louis, Kim, Jerome H, O'Connell, Robert J, Karasavvas, Nicos

“…The RV144 prime-boost regimen demonstrated efficacy against HIV acquisition while VAX003 and VAX004 did not. Although these trials differed by risk groups,…”
Get more information

Safe landing for global polio eradication: A perspective by Arita, Isao, Francis, Donald P

“…Abstract After over two decades of immense efforts, the global polio eradication initiative may be approaching its final phase. With leadership from WHO, great…”
Get full text

Protecting the public's health: remove the political constraints that hamper the Centers for Disease Control and Prevention by FRANCIS, Donald P

“…With a country as vast and complex as the United States, there is a huge need for technical expertise within its government. The fields of technical expertise…”
Get full text

Global vaccine supply. The increasing role of manufacturers from middle income countries by Francis, Donald P, Du, Yu-Ping, Precioso, Alexander R

“…Abstract Hallmarks in the remarkable evolution of vaccines and their application include the eradication of smallpox, the development and delivery of the early…”
Get full text

Successes and failures: Worldwide vaccine development and application by Francis, Donald P.

“…The impact that vaccines have had on world health has been great. The misery prevented and the lives saved have been impressive. But all has not been good. As…”
Get full text

WHO influenza vaccine technology transfer initiative: Role and activities of the Technical Advisory Group by Francis, Donald P, Grohmann, Gary

“…Abstract In May 2006, the WHO published a Global Pandemic Influenza Action Plan. A significant part of that plan involves the transfer of technology necessary…”
Get full text

The Need for a Global HIV Vaccine Enterprise by Klausner, Richard D., Fauci, Anthony S., Corey, Lawrence, Nabel, Gary J., Gayle, Helene, Berkley, Seth, Haynes, Barton F., Baltimore, David, Collins, Chris, Douglas, R. Gordon, Esparza, Jose, Francis, Donald P., Ganguly, N. K., Gerberding, Julie Louise, Johnston, Margaret I., Kazatchkine, Michel D., McMichael, Andrew J., Makgoba, Malegapuru W., Pantaleo, Giuseppe, Piot, Peter, Shao, Yiming, Tramont, Edmund, Varmus, Harold, Wasserheit, Judith N.

“…A new collaborative model of research is needed to increase resources, to prioritize the R agenda of the major public- and private-sector stakeholders, and…”
Get full text

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men by Hadler, S C, Francis, D P, Maynard, J E, Thompson, S E, Judson, F N, Echenberg, D F, Ostrow, D G, O'Malley, P M, Penley, K A, Altman, N L

“…To study the duration of antibody persistence and protection provided by the hepatitis B vaccine, we followed 773 homosexual men for five years after…”
Get more information

Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials by FRANCIS, Donald P, HEYWARD, William L, GULATI, Vineeta, WINSLOW, Nathan, GURWITH, Marc, SINANGIL, Faruk, BERMAN, Phillip W, POPOVIC, Vladimir, OROZCO-CRONIN, Patti, ORELIND, Karin, GEE, Carolyn, HIRSCH, Adrian, IPPOLITO, Tina, LUCK, Aimee, LONGHI, Michael

Get full text

Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX®B/E HIV vaccine trial, Bangkok, Thailand by VANICHSENI, Suphak, TAPPERO, Jordan W, PITISUTTITHUM, Punnee, KITAYAPORN, Dwip, MASTRO, Timothy D, VIMUTISUNTHORN, Eiam, VAN GRIENSVEN, Frits, HEYWARD, William L, FRANCIS, Donald P, CHOOPANYA, Kachit

“…To describe recruitment, screening and baseline characteristics of injection drug users (IDU) participating in a phase III HIV vaccine (AIDSVAX B/E; VaxGen,…”
Get full text